Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

FDA Expands Approved Lialda Uses

July 18, 2011 6:36 am | News | Comments

Shire plc announced that the U.S. Food and Drug Administration approved Lialda delayed release tablets for the maintenance of remission in patients with ulcerative colitis.


UVa Pushing Biotech Breakthroughs

July 18, 2011 6:24 am | News | Comments

For officials at the University of Virginia, spinning off biotechnology companies isn't an explicit goal. Rather, it's one of several techniques used to push breakthroughs from the academic world to the practical.


Medivation Study Data Likely to Boost Company

July 18, 2011 6:19 am | News | Comments

Initial results from a late-stage study of a potential prostate cancer treatment by Medivation Inc. will likely will be positive, according to a new report from Citi Investment Research & Analysis.


Levomilnacipran Performs Well in New Study

July 18, 2011 6:16 am | News | Comments

Forest Laboratories Inc. said a potential depression treatment that failed in a late-stage clinical trial announced earlier this year did well in another study of adults with major depressive disorder.


Results of Sarilumab in Rheumatoid Arthritis

July 15, 2011 7:56 am | News | Comments

Sanofi and Regeneron Pharmaceuticals Inc. announced results from Phase 2b trials in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) with sarilumab (REGN88/SAR153191), a novel, high-affinity, subcutaneously administered, fully-human antibody targeting the interleukin-6 receptor (IL-6R).


Teplizumab Shows Some Results in Phase 3 Study

July 15, 2011 7:51 am | News | Comments

MacroGenics, Inc. announced results from Protégé, a Phase 3 clinical study of teplizumab in type 1 diabetes.


Alemtuzumab in Multiple Sclerosis Results Reported

July 15, 2011 7:48 am | News | Comments

Sanofi and its subsidiary, Genzyme, announced positive results from Care-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif (high dose subcutaneous interferon beta-1a) in patients with relapsing-remitting multiple sclerosis (RRMS).


Verastem Raises $32 Million

July 15, 2011 7:43 am | News | Comments

Verastem, Inc. has raised $32 million through a Series B financing, the proceeds of which will support ongoing research and development and will progress drug candidates into clinical development.


Camels May Offer Nano-based Cancer Gene Therapy

July 15, 2011 7:40 am | News | Comments

Nanobodies produced by camels have unique properties, which can be used in future drug development.


Atomic Structure for Sodium Channel Discovered

July 15, 2011 7:35 am | News | Comments

Scientists at the University of Washington have determined the atomic architecture of a sodium channel.


Novo Nordisk Gains Approval for FlexTouch

July 15, 2011 7:31 am | News | Comments

Novo Nordisk has been granted approval by the European Commission for FlexTouch, a prefilled insulin pen.


Combined Therapy Extends Life, Diminishes Pain

July 15, 2011 7:01 am | News | Comments

Approximately five to ten percent of patients with primary or metastatic cancer suffer from devastating neurological complications such as headaches, seizures, confusion, difficulty swallowing, and visual disturbances.



July 15, 2011 6:46 am | Product Releases | Comments

The Genevac Rocket Evaporator is a powerful tool proven to accelerate traditionally difficult and time consuming chiral separation and natural product sample preparation tasks.


Next-Gen Sequencing

July 15, 2011 6:41 am | Product Releases | Comments

Accelrys, Inc. announced significant enhancements to its NGS Collection for Pipeline Pilot includes dozens of new analysis pipelines for organizations seeking a single platform to support a wide variety of NGS applications.


Almac to Test Alzheimer’s Diagnostic

July 15, 2011 6:22 am | News | Comments

Almac’s Diagnostics business unit announced that it will be the central service lab to perform the analytic phase and deliver to the clinicians the result of Exonhit AclarusDx diagnostic test.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.